The research team, led by Romgase Sakamula and corresponding author Somponnat Sampattavanich, set out to address a well-recognized limitation in clinical oncology. PD-L1 expression, the protein biomarker currently used to guide immunotherapy decisions in lung cancer, has limited predictive performance on its own. Many patients with high PD-L1 scores fail to respond, while some with low scores experience remarkable tumor regression. Emerging evidence has pointed toward a more nuanced explanation: therapeutic response depends not merely on the abundance of immune cells within a tumor but on their spatial organization, the intricate architecture of cellular neighborhoods that determines whether killer T cells can actually reach and engage their malignant targets.

To capture this architecture, the investigators employed tissue-based cyclic immunofluorescence, abbreviated t-CyCIF, a technique that repeatedly stains the same tissue section with fluorescently labeled antibodies, imaging one round of markers after another and stripping the signal between cycles. By iterating this process, the team built a 13-marker panel capable of single-cell phenotyping across preserved archival tissue. This approach allowed them to identify individual cell types, including cytotoxic T cells, regulatory immune populations, and tumor cells, while retaining the exact positional relationships among them, something that dissociative methods such as single-cell sequencing of suspended cells cannot preserve.

The cohort consisted of seventeen pre-treatment specimens from patients with non-small cell lung cancer who subsequently received immune checkpoint inhibitors in a real-world clinical setting. Ten of these patients responded to therapy and seven did not. When the researchers first compared global measures, the density of immune cells and tumor cells across whole samples, they found no significant differences between the two groups. This null result is itself instructive, reinforcing the growing consensus that bulk cellular counts obscure the biologically meaningful features of the tumor microenvironment. The decisive information, the study suggests, resides in spatial relationships rather than simple abundance.

Because spatial analysis requires intact tissue architecture, the team focused their most detailed geometric investigations on a subset of resection specimens with preserved structure, comprising four responders and three non-responders. Within these samples they examined several layers of organization: lymphoid structures, cellular neighborhoods, pairwise distances between cell populations, and higher-order tissue architecture. Metrics related to tertiary lymphoid structures, organized aggregates of immune cells that form within tumors and are thought to serve as sites of local immune activation, showed a trend toward higher values in responders, hinting at greater immune organization within their tumors, although the small sample size means this observation requires validation in larger cohorts.

The cellular neighborhood analysis produced some of the study’s most striking findings. In responder tumors, regions enriched for cytotoxic T cells and for vasculature were significantly expanded, whereas non-responder tumors displayed a predominantly tumor-centered spatial architecture, with malignant cells dominating the landscape and immune populations relegated to the periphery. This distinction implies that the gross topological layout of a tumor, whether immune activity is woven into its core or pushed to its margins, may fundamentally shape how the tumor responds to checkpoint blockade, which works by releasing the brakes on T cells that must be in physical proximity to cancer cells to kill them.

Perhaps the most compelling discovery centered on the perivascular niche, the zone immediately surrounding tumor blood vessels. Responders exhibited shorter distances between vessels and cytotoxic T cells, along with greater enrichment of cytotoxic and PD-1-positive cytotoxic T cells in these perivascular regions. Higher-order spatial analysis further highlighted the preferential organization of PD-1-positive cytotoxic T cells within vascular-associated niches in responder tumors. This arrangement carries mechanistic significance: PD-1 is the receptor targeted by checkpoint inhibitors such as pembrolizumab and nivolumab, and PD-1-positive T cells positioned near vessels are plausibly the cells most accessible to circulating antibody drugs and best positioned to traffic between the bloodstream and the tumor parenchyma. A tumor that stations its exhausted-but-revivable killer cells along its vascular highways may be primed for checkpoint release in a way that a tumor with sequestered, disorganized immune infiltrates is not.

These findings carry substantial implications for biomarker development. If validated, perivascular immune organization could serve as a complementary predictive framework, layered alongside PD-L1 testing to refine patient selection for immunotherapy. The technical requirements are notable but feasible: the analysis relies on formalin-fixed paraffin-embedded archival tissue, the standard specimen type held by pathology departments worldwide, and cyclic immunofluorescence can in principle be implemented on existing clinical material. Spatial biology platforms of this kind are advancing rapidly across oncology, and this study demonstrates their application to a clinically urgent question using a modest number of samples and a real-world patient population rather than a curated trial cohort.

Important caveats temper the enthusiasm. The study analyzed seventeen patients overall, with spatial analyses restricted to seven resection specimens, numbers far too small to support clinical decision-making. The reported trends, including the tertiary lymphoid structure metrics, will need confirmation in larger, independent, and ideally prospective cohorts before spatial biomarkers can enter routine practice. The retrospective design, approved by the Siriraj Institutional Review Board with the informed consent requirement waived, also means that treatment regimens and follow-up were not standardized as they would be in a controlled trial. Nevertheless, the consistency of the spatial signal, emerging across multiple independent analytical approaches, lends credibility to the central conclusion.

The study, funded by the National Research Council of Thailand, the Siriraj Foundation, and the Siriraj Research Development Fund, adds to a rapidly accumulating body of evidence that cancer immunology must be read in three dimensions. The tumor microenvironment is not a well-mixed soup of cells but a structured tissue, with vascular corridors, lymphoid aggregates, and territorial neighborhoods that govern immune surveillance. As the authors demonstrate, the difference between a tumor that succumbs to immunotherapy and one that resists it may be written into that geography before the first dose of treatment is ever given. For patients with non-small cell lung cancer, the road to personalized immunotherapy may soon run through the perivascular spaces of their own tumors.

Subject of Research: Spatial organization of perivascular immune cells as a biomarker for immunotherapy response in non-small cell lung cancer

Article Title: Perivascular immune organization and spatial architecture are associated with immunotherapy response in non-small cell lung cancer

Article References: Sakamula, R., Likhityungyuen, T., Anekpuritanang, T., Korphaisarn, K., & Sampattavanich, S. (2026). Perivascular immune organization and spatial architecture are associated with immunotherapy response in non-small cell lung cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04549-y

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04549-y

Keywords: non-small cell lung cancer, immunotherapy, immune checkpoint inhibitors, tumor microenvironment, spatial biology, perivascular immune niche, cyclic immunofluorescence, PD-L1, cytotoxic T cells, tertiary lymphoid structures, biomarker, tumor vasculature

The tumor-specific target at the heart of the study is epidermal growth factor receptor variant III, or EGFRvIII. This mutant arises through a characteristic in-frame deletion within the EGFR gene, producing a truncated receptor that carries a novel junction sequence not found in any healthy tissue. That specificity makes EGFRvIII an attractive bullseye: a CAR directed against it should, in principle, spare normal cells entirely. EGFRvIII is well known in glioblastoma, but it also appears in a subset of head and neck squamous cell carcinomas, a cancer type that remains difficult to treat because of heterogeneous antigen expression and a strongly immunosuppressive tumor microenvironment. The catch, as the authors emphasize, is that EGFRvIII in HNSCC is expressed at low levels and often unevenly across tumor cells, which limits how much killing a single-target CAR can achieve.

Full-length EGFR, the parent protein of the variant, presents the opposite dilemma. It is frequently overexpressed on HNSCC cells, offering an abundant surface marker, but it is also present on normal epithelial tissues in skin, gut and other organs. A directly activating CAR against full-length EGFR would therefore risk serious on-target, off-tumor toxicity. The German team’s insight was to exploit EGFR abundance without paying that price: instead of making EGFR a killing trigger, they converted it into a purely adhesive anchor. They built a non-signaling CAR (nsCAR) whose recognition domain was derived from Cetuximab, a clinically established monoclonal antibody that binds EGFR. Crucially, the Cetuximab epitope is retained in EGFRvIII, meaning the nsCAR can engage both the abundant full-length receptor and the mutant variant on tumor cells, while the signaling CAR provides the actual activation cue through EGFRvIII.

To test the concept, the researchers engineered primary human T-cells—obtained from healthy adult donors with informed consent under a protocol approved by the ethics committee of Universitätsklinikum Düsseldorf—to express EGFRvIII-specific signaling CARs either alone or together with the EGFR-directed nsCAR. They then confronted these engineered cells with HNSCC cell lines engineered to display defined levels of EGFRvIII, allowing the team to dissect how target antigen density shapes therapeutic performance. Functional output was quantified with in vitro cytotoxicity assays and time-resolved killing dynamics, so the investigators could follow not just how many tumor cells died but how quickly the engineered T-cells dispatched them.

The baseline behavior of the EGFRvIII CAR T-cells followed a familiar rule of CAR biology: cytotoxicity was clearly dependent on target antigen density. When tumor cells displayed plentiful EGFRvIII, the signaling CAR alone performed well; when antigen was scarce, killing faltered. Against that backdrop, the co-expressed nsCAR produced its most interesting effects. Adding the non-signaling receptor specifically enhanced tumor cell killing in selected combinations of CAR construct and target antigen, and the strongest gains appeared precisely where baseline CAR activity was limited—the very situation that mirrors the low, heterogeneous EGFRvIII expression seen in actual HNSCC patients. Importantly, the nsCAR by itself was non-cytotoxic, confirming that the inert receptor could not trigger T-cell activation on its own and would not, in theory, direct killing toward healthy EGFR-expressing tissue.

Why should a receptor that cannot signal improve killing at all? The authors turned to fluorescence microscopy to answer that question at the level of cell-to-cell contact. Their imaging revealed co-localization of CAR and nsCAR molecules at the immunological synapse—the specialized junction that forms between a T-cell and its target, through which perforin, granzymes and other lethal payloads are delivered. This observation suggests a mechanical explanation: by binding full-length EGFR across a broader surface of the tumor cell, the nsCAR helps stabilize and broaden the contact interface, effectively increasing the dwell time and the local concentration of engagement even when the activating antigen is sparsely distributed. In effect, the nsCAR acts as a molecular Velcro strip that holds the two cells together long enough for the signaling CAR to do its work.

The modular nature of the approach is one of its most appealing features. Because the nsCAR contributes adhesion rather than activation, it can in principle be paired with different signaling CARs without redesigning the killing machinery, and the safety profile of the activating receptor remains anchored to a truly tumor-specific antigen. The study also illustrates a broader design principle for the field: antigen density thresholds, long a source of failure in solid tumor CAR therapy, can potentially be lowered not only by tuning the signaling CAR itself but by recruiting a second, abundant antigen into the synapse as a silent partner. Dual-epitope engagement of this kind decouples the question of where the T-cell attacks from the question of how strongly it is activated.

The authors are careful to frame their findings as an in vitro proof of concept. All experiments were conducted in cell lines with defined antigen levels rather than in animal models or patient-derived tumor tissue, and the immunosuppressive microenvironment that plagues real HNSCC was not reproduced in the dish. The enhancement effect was also selective, appearing in particular CAR and antigen combinations rather than universally, which means the engineering choices—affinity, spacer design, expression levels of each receptor—will need careful optimization. The team notes that the strategy warrants further evaluation in more complex preclinical models, where factors such as antigen heterogeneity in three dimensions, stromal barriers and competing immune signals will test whether the synapse-stabilizing benefit survives outside the controlled laboratory setting.

Even with those caveats, the study adds a genuinely novel tool to the solid tumor CAR toolbox. Head and neck squamous cell carcinomas claim hundreds of thousands of lives worldwide each year, and patients whose disease resists surgery, radiation and chemotherapy have few options. A therapy that keeps its activation trigger locked onto a tumor-only mutation like EGFRvIII, while borrowing the abundance of a normal-tissue protein like full-length EGFR purely for grip, offers a way to thread the needle between efficacy and safety. If the non-signaling co-receptor concept holds up in animal models and, eventually, clinical testing, the paradox of the receptor that cannot kill may become one of immunotherapy’s quieter but more useful inventions—a reminder that in the intricate choreography of immune cell contact, sometimes the strongest attack begins with simply holding on.

Subject of Research: Non-signaling CAR co-expression to enhance EGFRvIII-specific CAR T-cell cytotoxicity in head and neck squamous cell carcinoma

Article Title: Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma

Article References: Grueter, K., Sander, N., Coen, L., Hüsken, S., Kleinfelder, E., Haist, C., Blaeschke, F., Scheckenbach, K., Monzel, C., Hanenberg, H., & Wiek, C. (2026). Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma. BMC Cancer, 26(1), Article 1149. https://doi.org/10.1186/s12885-026-17058-z

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17058-z

Keywords: CAR T-cell therapy, EGFRvIII, head and neck squamous cell carcinoma, non-signaling CAR, immunotherapy, tumor-specific antigen, antigen density, immunological synapse, Cetuximab, EGFR, cytotoxic T cells, targeted therapy

The enzyme in question is lysine methyltransferase 9, or KMT9, a histone-modifying protein that previous work from the same group had already implicated in prostate tumor growth and androgen receptor signaling. In the new study, published in the journal Molecular Cancer, Jon Peñarando, Eric Metzger, Roland Schüle, and colleagues demonstrate that KMT9 does far more than drive cancer cell proliferation. It actively constructs the molecular barriers that prevent the immune system from recognizing and destroying the tumor, making it a uniquely attractive target for combination approaches designed to sensitize prostate cancer to immunotherapy.

At the center of the discovery is a chemokine signaling axis that functions as a cellular summons for immunosuppressive cells. The researchers found that KMT9 regulates the expression of C-X-C motif chemokine ligands, including CXCL5, which are secreted by prostate tumor cells and bind to the C-X-C motif chemokine receptor 2, CXCR2, on the surface of circulating myeloid cells. This ligand-receptor interaction acts as a homing beacon, drawing polymorphonuclear myeloid-derived suppressor cells, or PMN-MDSCs, into the tumor. Once recruited, these cells populate the tumor immune microenvironment in large numbers, creating a dense myeloid shield around the malignant glands.

PMN-MDSCs are among the most potent enemies of antitumor immunity. They suppress cytotoxic T cell responses through multiple mechanisms, including depletion of the amino acid arginine, production of reactive oxygen species, and interference with T cell trafficking. Using genetically engineered mouse models of prostate cancer in which Pten and Trp53, two frequently altered tumor suppressor genes, are deleted in prostate epithelium, the team showed that tumors with intact KMT9 were heavily infiltrated by these suppressive myeloid cells. When the researchers ablated the Kmt9a gene specifically in the prostate, the picture changed dramatically: PMN-MDSC recruitment collapsed, and cytotoxic T cells flooded into the tumor glands, showing clear signs of activation such as granzyme B expression.

The spatial dimension of this effect proved just as important as the cellular one. Advanced single-cell spatial phenotyping revealed that in tumors with functional KMT9, cytotoxic T cells were largely excluded from the tumor epithelium, lingering instead in the surrounding stroma where they could not make contact with their targets. This immune-excluded pattern is one of the recognized hallmarks of tumors that resist checkpoint blockade, since drugs like anti-PD-1 antibodies can only reinvigorate T cells that are physically close to the cancer cells they are meant to kill. Loss of KMT9 converted this excluded architecture into an inflamed, T cell-infiltrated landscape, precisely the configuration associated with immunotherapy responsiveness.

But KMT9’s contribution to immune evasion did not end with recruitment of suppressor cells. In a second, mechanistically distinct arm of the study, the researchers found that KMT9 also arms the tumor cells themselves against T cell attack. Chromatin immunoprecipitation sequencing showed that KMT9 binds directly to the promoter of the gene encoding arginase 1, ARG1, an enzyme that catabolizes L-arginine, an amino acid essential for T cell function and proliferation. By driving ARG1 expression in prostate tumor cells, KMT9 renders them resistant to T cell-mediated cytotoxicity, effectively allowing them to survive even when killer lymphocytes do manage to engage them.

The therapeutic implications of this dual mechanism were tested in preclinical experiments. When mice carrying Kmt9a-deficient prostate tumors were treated with SB225002, a CXCR2 inhibitor, tumor growth was inhibited to a greater degree than with either intervention alone, confirming that the chemokine axis is a clinically relevant vulnerability downstream of KMT9. Similarly, combining Kmt9a loss with numidargistat, a pharmacological inhibitor of ARG1, produced enhanced suppression of tumor growth. These combination experiments suggest that even partial disruption of the KMT9 pathway could be amplified by drugs that target the individual immune-evasion mechanisms it controls.

Importantly, the team connected their mouse findings to human disease by analyzing data from the TCGA prostate adenocarcinoma cohort, which comprises 500 prostate tumor samples and 52 healthy prostate controls. The analysis showed that KMT9 expression is elevated in prostate tumors relative to normal tissue and that high KMT9 levels correlate with shorter progression-free survival, underscoring the clinical relevance of the pathway. The consistency between the murine genetic models, the human genomic data, and the pharmacological studies lends considerable weight to the conclusion that KMT9 is not an artifact of a single experimental system but a genuine driver of immune evasion in prostate cancer.

For a field searching for ways to unlock immunotherapy in prostate cancer, the study offers a compelling conceptual framework. Rather than targeting the tumor’s defenses one at a time, inhibiting KMT9 would strike at the epigenetic master switch that controls both the recruitment of immunosuppressive myeloid cells through CXCR2 ligand expression and the intrinsic resistance of tumor cells through ARG1. Ablation of KMT9α in the mouse models produced inhibition of prostate tumor growth accompanied by a massive reduction in PMN-MDSC recruitment and a significant increase in cytotoxic T cell activation and infiltration of the tumor glands, a triple effect that few single agents have achieved in this disease.

Considerable work remains before these findings reach the clinic. KMT9 inhibitors are still in early stages of development, and the safety of systemically targeting a methyltransferase with functions in normal tissue is not yet established. The study’s authors note that their findings establish KMT9 as a therapeutic target to reprogram the immunosuppressive landscape and potentially improve the clinical efficacy of current immunotherapies, a formulation that anticipates future trials combining KMT9-directed agents with checkpoint blockade. If those efforts succeed, the stubborn resistance of prostate cancer to immunotherapy, one of the most frustrating puzzles in modern oncology, may finally begin to yield, not to a smarter antibody or a stronger checkpoint inhibitor, but to an epigenetic enzyme that had been quietly building the tumor’s defenses all along.

Subject of Research: The role of the lysine methyltransferase KMT9 in shaping the immunosuppressive tumor immune microenvironment of prostate cancer

Article Title: KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer

Article References: Peñarando, J., Willmann, D., Sum, M., Jia, Y., Berlin, C., Braun, L. M., Chen, Z., Urban, S., Jung, M., Duteil, D., Metzger, D., Gratzke, C., Zeiser, R., Greschik, H., Schüle, R., & Metzger, E. (2026). KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer. Molecular Cancer. https://doi.org/10.1186/s12943-026-02801-8

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02801-8

Keywords: KMT9, prostate cancer, tumor immune microenvironment, PMN-MDSCs, CXCL5, CXCR2, ARG1, cytotoxic T cells, cancer immunotherapy, epigenetics, histone methyltransferase, immune evasion